Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2011 1
2012 4
2013 3
2014 1
2015 1
2016 2
2017 5
2018 4
2019 2
2021 1
2022 5
2023 5
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

34 results

Results by year

Filters applied: . Clear all
Page 1
Continuous venetoclax in treatment-naive TP53 disrupted patients with chronic lymphocytic leukemia: A chronic lymphocytic leukemia campus study.
Visentin A, Mauro FR, Scarfò L, Gentile M, Farina L, Reda G, Ferrarini I, Proietti G, Derenzini E, Cibien F, Vitale C, Sanna A, Pietrasanta D, Marchetti M, Murru R, Rigolin GM, Sportoletti P, Trimarco V, Cavarretta CA, Angotzi F, Cellini A, Ruocco V, Zatta I, Laurenti L, Molica S, Coscia M, Ghia P, Foà R, Cuneo A, Trentin L. Visentin A, et al. Among authors: sanna a. Am J Hematol. 2023 Sep;98(9):E237-E240. doi: 10.1002/ajh.27009. Epub 2023 Jun 29. Am J Hematol. 2023. PMID: 37382471 No abstract available.
PIEZO1 mutations impact on early clinical manifestations of myelodysplastic syndromes.
Attardi E, Andolfo I, Russo R, Tiberi L, Raddi MG, Rosato BE, Marra R, Formicola D, Del Giudice F, Brogi A, Consagra A, Amato C, Sanna A, Artuso R, Iolascon A, Santini V. Attardi E, et al. Among authors: sanna a. Am J Hematol. 2023 Apr;98(4):E72-E75. doi: 10.1002/ajh.26863. Epub 2023 Feb 14. Am J Hematol. 2023. PMID: 36695705 Free article. No abstract available.
Relative dose intensity of obinutuzumab-chlorambucil in chronic lymphocytic leukemia: a multicenter Italian study.
Fresa A, Autore F, Piciocchi A, Catania G, Visentin A, Tomasso A, Moretti M, Vitale C, Chiarenza A, Morelli F, Sportoletti P, Marasca R, Sapienza G, Cuccaro A, Murru R, Sanna A, Patti C, Angeletti I, Coscia M, Trentin L, Pietrasanta D, Innocenti I, Laurenti L. Fresa A, et al. Among authors: sanna a. Blood Adv. 2022 Jul 12;6(13):3875-3878. doi: 10.1182/bloodadvances.2022006964. Blood Adv. 2022. PMID: 35789375 Free PMC article. No abstract available.
How COVID-19 pandemic changed our attitude to venetoclax-based treatment in chronic lymphocytic leukemia.
Deodato M, Frustaci AM, Sportoletti P, Laurenti L, Murru R, Visentin A, Reda G, Mauro FR, Quaresmini G, Vanazzi A, Vitale C, Orsucci L, Massaia M, Sanna A, Motta M, Ibatici A, Ferrarini I, Borella C, Varettoni M, Tani M, Marinoni S, Ferrario A, Zamprogna G, Montillo M, Tedeschi A. Deodato M, et al. Among authors: sanna a. Leuk Lymphoma. 2022 Aug;63(8):1985-1988. doi: 10.1080/10428194.2022.2053532. Epub 2022 Mar 27. Leuk Lymphoma. 2022. PMID: 35343363 No abstract available.
Management of chronic lymphocytic leukemia in Italy during a one year of the COVID-19 pandemic and at the start of the vaccination program. A Campus CLL report.
Cuneo A, Rigolin GM, Coscia M, Quaresmini G, Scarfò L, Mauro FR, Motta M, Quaglia FM, Trentin L, Ferrario A, Laurenti L, Reda G, Ferrari A, Pietrasanta D, Sportoletti P, Re F, De Paoli L, Foglietta M, Giordano A, Marchetti M, Farina L, Del Poeta G, Varettoni M, Chiurazzi F, Marasca R, Malerba L, Ibatici A, Tisi MC, Stefoni V, Leone M, Baratè C, Olivieri J, Murru R, Gentile M, Sanna A, Gozzetti A, Gattei V, Gottardi D, Derenzini E, Levato L, Orsucci L, Penna G, Chiarenza A, Foà R. Cuneo A, et al. Among authors: sanna a. Hematol Oncol. 2021 Oct;39(4):570-574. doi: 10.1002/hon.2899. Epub 2021 Jul 13. Hematol Oncol. 2021. PMID: 34258787 Free PMC article. No abstract available.
Obinutuzumab plus chlorambucil versus ibrutinib in previously untreated chronic lymphocytic leukemia patients without TP53 disruptions: A real-life CLL campus study.
Visentin A, Mauro FR, Catania G, Fresa A, Vitale C, Sanna A, Mattiello V, Cibien F, Sportoletti P, Gentile M, Rigolin GM, Quaglia FM, Murru R, Gozzetti A, Molica S, Marchetti M, Pravato S, Angotzi F, Cellini A, Scarfò L, Reda G, Coscia M, Laurenti L, Ghia P, Foà R, Cuneo A, Trentin L. Visentin A, et al. Among authors: sanna a. Front Oncol. 2022 Nov 21;12:1033413. doi: 10.3389/fonc.2022.1033413. eCollection 2022. Front Oncol. 2022. PMID: 36479077 Free PMC article.
Rapid evaluation of T cell clonality in the diagnostic work-up of mature T cell neoplasms: TRBC1-based flow cytometric assay experience.
Capone M, Peruzzi B, Palterer B, Bencini S, Sanna A, Puccini B, Nassi L, Salvadori B, Statello M, Carraresi A, Stefanelli S, Orazzini C, Minuti B, Caporale R, Annunziato F. Capone M, et al. Among authors: sanna a. Transl Oncol. 2022 Dec;26:101552. doi: 10.1016/j.tranon.2022.101552. Epub 2022 Sep 30. Transl Oncol. 2022. PMID: 36183675 Free PMC article.
34 results